Answers are grounded in this paper and cite their sources.
// Ingrid Cifola 1, * , Marta Lionetti 2, 3, * , Eva Pinatel 1 , Katia Todoerti 4 , Eleonora Mangano 1 , Alessandro Pietrelli 1 , Sonia Fabris 2, 3 , Laura Mosca 2, 3 , Vittorio Simeon 4 , Maria Teresa Petrucci 5 , Fortunato Morabito 6 , Massimo Offidani 7 , Francesco Di Raimondo 8 , Antonietta Falcone 9 , Tommaso Caravita 10 , Cristina Battaglia 1, 11 , Gianluca De Bellis 1 , Antonio Palumbo 12 , Pellegrino Musto 13 , Antonino Neri 2, 3 1 Institute for Biomedical Technologies, National Research Council, Milan, Italy 2 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy 3 Hematology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 4 Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy 5 Hematology, Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy 6 Hematology Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy 7 Hematologic Clinic, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy 8 Department of Biomedical Sciences, Division of Hematology, Ospedale Ferrarotto, University of Catania, Catania, Italy 9 Hematology Unit, IRCCS “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy 10 Department of Hematology, Ospedale S. Eugenio, Tor Vergata University, Rome, Italy 11 Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy 12 Division of Hematology, University of Torino, A.O.U. San Giovanni Battista, Torino, Italy 13 Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy * These authors have contributed equally to this work Correspondence to: Antonino Neri, e-mail: antonino.neri@unimi.it Ingrid Cifola, e-mail: ingrid.cifola@itb.cnr.it Keywords: whole-exome sequencing, plasma cell leukemia, multiple myeloma, mutations Received: April 29, 2015 Accepted: May 11, 2015 Published: May 25, 2015 ABSTRACT Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma cell dyscrasia and may represent a valid model for high-risk multiple myeloma (MM). To provide novel information concerning the mutational profile of this disease, we performed the whole-exome sequencing of a prospective series of 12 pPCL cases included in a Phase II multicenter clinical trial and previously characterized at clinical and molecular levels. We identified 1, 928 coding somatic non-silent variants on 1, 643 genes, with a mean of 166 variants per sample, and only few variants and genes recurrent in two or more samples. An excess of C > T transitions and the presence of two main mutational signatures (related to APOBEC over-activity and aging) occurring in different translocation groups were observed. We identified 14 candidate cancer driver genes, mainly involved in cell-matrix adhesion, cell cycle, genome stability, RNA metabolism and protein folding. Furthermore, integration of mutation data with copy number alteration profiles evidenced biallelically disrupted genes with potential tumor suppressor functions. Globally, cadherin/Wnt signaling, extracellular matrix and cell cycle checkpoint resulted the most affected functional pathways. Sequencing results were finally combined with gene expression data to better elucidate the biological relevance of mutated genes. This study represents the first whole-exome sequencing screen of pPCL and evidenced a remarkable genetic heterogeneity of mutational patterns. This may provide a contribution to the comprehension of the pathogenetic mechanisms associated with this aggressive form of PC dyscrasia and potentially with high-risk MM.
No takes yet. Share an insight, caveat, or question.
Cifola et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: